Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Pharmacokinetic Evaluation Of Pixantrone For The Treatment Of Non-Hodgkin's Lymphoma
M. Jamal-Hanjani, R. Pettengell
Published 2011 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Introduction: Pixantrone is a novel aza-anthracenedione, similar in structure to anthracyclines, including the anthracycline derivative mitoxantrone. There is no standard therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who have received two prior lines of therapy. Pixantrone does not bind iron, promotes reactive oxygen species to a lesser degree than other anthracyclines and is therefore believed to be less cardiotoxic without compromising efficacy. Areas covered: This article outlines the chemical properties of pixantrone, as well as the preclinical and clinical studies looking at pixantrone in the treatment of both indolent and aggressive NHL. Expert opinion: Pixantrone is an active and safe drug that has been shown to be of benefit when used to treat patients with relapsed aggressive NHL in the context of Phase II and Phase III studies. It was superior to other single-agent therapies in this context and in combination therapy may be the treatment of choice in order to avoid cardiac toxicity. Potentially it is a more effective and less cardiotoxic alternative to doxorubicin in patients with aggressive NHL.
This paper references
Preliminary results of a phase II trial with the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL)
A Guidetti (2009)
Bbr 2778, an Aza-anthracenedione Endowed with Preclinical Anticancer Activity and Lack of Delayed Cardiotoxicity
G. Beggiolin (2001)
The pivotal Phase III PIX301 (EXTEND) trial
Comparative trail of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/ refractory indolent non-Hodgkin’s lymphoma (NHL)
A Santoro (2006)
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
P. Borchmann (2011)
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
S. Swain (2003)
Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
L. El-Helw (2009)
Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study
N. Macpherson (2006)
CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity
Benny J. Evison (2009)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
J. W. Friedberg (2010)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
A. Goy (2005)
Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
A. Santoro (2006)
Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.
E. C. van Dalen (2004)
Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity.
W. Denny (1990)
Phase II studies of pixantrone
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma
T. P. Srokowski (2011)
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone
E. Cavalletti (2007)
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
P. Borchmann (2003)
New developments in anthracycline-induced cardiotoxicity.
A. Mordente (2009)
Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.
W. Wilson (2008)
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
A. P. Krapcho (1994)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
A. Stopeck (2009)
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
E. Rodriguez-Monge (1997)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.
M. Hacker (2009)
A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
S. Faivre (2001)
Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
A. Guidetti (2009)
CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituxamib) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.
R. Herbrecht (2007)
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
M. Jerkeman (2004)
Long-term follow-up of platinum-based lymphoma salvage regimens
EJ Rodriguez-Monge (1997)
Preclinical studies of pixantrone
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
M. Reiser (1998)
F. Otero (2000)
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent
Ben J. Evison (2007)
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma
D. Mukherji (2010)
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
C. Gisselbrecht (2010)
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
P. Wiernik (2008)
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
W. Velasquez (1988)
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma
F. Zaja (2006)
Pixantrone maleate for non-Hodgkin's lymphoma.
D. Mukherji (2009)
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
T. Witzig (2011)
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.
L. Dawson (2000)
Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.
R. Pettengell (2010)
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma
S. Lim (2007)
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
P. Borchmann (2001)
Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma
B. Pro (2008)
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.
L. Hazlehurst (1995)
Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets
Benny J. Evison (2008)
This paper is referenced by
Lead Identification, Optimization and Characterization of Novel Cancer Treatment Strategies Using Repositioned Drugs
D. Taylor (2013)
Anti Cancer: DNA Topoisomerase Inhibitors
W. Denny (2013)
Pixantrone: merging safety with efficacy
D. Papadatos-Pastos (2013)
Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds
J. Liu (2012)